argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

Impact · against what's priced in

The acquisition of Unnatural Products is a diversification play that expands argenx's discovery toolkit beyond antibodies, but it is not a primary valuation driver. While it adds long-term optionality for oral medicines, the market's current focus remains on the immediate commercial uptake of the Vyvgart franchise and myositis approvals.

ARGX+0.15

Not in the price yet

In context

The $1.15 billion acquisition of a macrocyclic peptide engine adds a new modality for oral and long-acting medicines that is not part of the existing valuation focused on the Vyvgart franchise and the Forte acquisition.